Opendata, web and dolomites

TRIGGDRUG SIGNED

Reactions That Translate mRNA into Drug-like Molecules

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TRIGGDRUG project word cloud

Explore the words cloud of the TRIGGDRUG project. It provides you a very rough idea of what is the project "TRIGGDRUG" about.

transfer    deregulated    protein    induce    synthesis    caused    look    peptides    instructors    small    peptidomimetics    formed    provides    triggered    inside    active    genes    turnover    worlds    chemical    molecular    generation    cell    drug    identity    read    death    therapy    cancer    reactive    opportunity    acid    mutation    reactivity    output    idea    data    patient    cope    rna    rewire    template    form    apoptosis    transcriptome    expression    chemistry    sequencing    personalized    amplification    hijack    recognition    healthy    promoted    gene    acyl    translocation    molecule    validated    cellular    how    express    kinase    2040    molecules    synergy    nucleic    harnessed    activated    nutshell    tool    inhibitors    mrna    translate    couple    photodynamic    advantage    expressed    copy    cells    single    reactions    alkylidene    eliminate    cure    aberrantly    inhibition    disease    triggers    sequence    accordingly    reaction    perturbation   

Project "TRIGGDRUG" data sheet

The following table provides information about the project.

Coordinator
HUMBOLDT-UNIVERSITAET ZU BERLIN 

Organization address
address: UNTER DEN LINDEN 6
city: BERLIN
postcode: 10117
website: www.hu-berlin.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 2˙470˙400 €
 EC max contribution 2˙470˙400 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2014-ADG
 Funding Scheme ERC-ADG
 Starting year 2016
 Duration (year-month-day) from 2016-01-01   to  2020-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HUMBOLDT-UNIVERSITAET ZU BERLIN DE (BERLIN) coordinator 2˙470˙400.00

Map

 Project objective

How could a molecular cancer therapy look like in 2040? In cancer, gene expression is deregulated due to amplification, mutation and translocation of genes. Next generation RNA sequencing provides us with the opportunity to identify the number and identity of the gene products aberrantly expressed in a patient. But do we have methods that take advantage of the personalized sequence data? In this research project we propose the idea to use the RNA molecules expressed upon disease-type gene expression as instructors for the chemical synthesis of drug-like molecules that cure the disease. Accordingly, drug-like molecules would only be formed in those cells that express the disease-specific RNA molecules. Such a personalized molecular therapy would eliminate side effects caused by unwanted perturbation of healthy cells. The idea to use cellular RNA molecules as triggers for drug synthesis requires methods that couple RNA recognition with a change of chemical reactivity. Reactive molecules must be able to “read” and “translate” the sequence of a RNA molecule into a drug-like output. We will develop mRNA-triggered reactions that i) proceed with turnover in template to cope with low mRNA copy numbers and ii) allow the single-step synthesis of highly active drug-like molecules to address deregulated protein targets inside cancer cells. To achieve this aim, we will advance chemical acyl transfer and alkylidene transfer reactions. The reactions on disease-specific mRNA will form peptides/peptidomimetics/small molecule-based kinase inhibitors which will induce apoptosis in cancer cells. We will target validated drug targets. Synergy between the nucleic acid and protein worlds will be harnessed. Furthermore, we will develop a RNA-promoted reaction with turnover beyond product inhibition. This will enable a transcriptome-activated photodynamic therapy. In a nutshell, we will develop a chemistry-based tool to hijack disease mRNA and rewire the cell death program.

 Publications

year authors and title journal last update
List of publications.
2018 Jasmine Chamiolo, Ge‐min Fang, Felix Hövelmann, Dhana Friedrich, Andrea Knoll, Alexander Loewer, Oliver Seitz
Comparing Agent‐Based Delivery of DNA and PNA Forced Intercalation (FIT) Probes for Multicolor mRNA Imaging
published pages: , ISSN: 1439-4227, DOI: 10.1002/cbic.201800526
ChemBioChem 2019-04-18

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRIGGDRUG" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TRIGGDRUG" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

Aware (2019)

Aiding Antibiotic Development with Deep Analysis of Resistance Evolution

Read More  

Resonances (2019)

Resonances and Zeta Functions in Smooth Ergodic Theory and Geometry

Read More  

PonD (2019)

Particles-on-Demand for Multiscale Fluid Dynamics

Read More